Oncology – Breast
M-A | Adjuvant chemotherapy for resected triple negative breast cancer patients
24 Feb, 2023 | 13:30h | UTC
SR | Psychological interventions for women with non‐metastatic breast cancer
23 Feb, 2023 | 13:19h | UTCPsychological interventions for women with non‐metastatic breast cancer – Cochrane Library
RCT | Breast-conserving surgery without irradiation may be an option for older patients with early breast cancer
17 Feb, 2023 | 13:25h | UTCSummary: The article reports a phase 3 randomized trial that investigated the efficacy of omitting irradiation after breast-conserving surgery in women aged 65 years or older with hormone receptor-positive, node-negative, T1 or T2 primary breast cancer, and tumors ≤3 cm in the largest dimension, who received adjuvant endocrine therapy. A total of 1326 women were enrolled, with 658 receiving whole-breast irradiation and 668 receiving no irradiation. The results showed that the omission of radiotherapy led to an increased incidence of local breast cancer recurrence but had no negative effect on distant recurrence as the first event or overall survival. The study suggests that omission of radiotherapy could be a viable treatment option for older women with low-risk, hormone receptor–positive early breast cancer who receive adjuvant endocrine therapy.*
Article: Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
For many older breast cancer patients, study finds radiation doesn’t affect survival – STAT
Do Older Patients Need Radiation Rx After Breast Cancer Surgery? – HealthDay
*Note: This summary was created through the collaboration of a medical editor and ChatGPT.
M-A | Financial toxicity among patients with breast cancer worldwide
17 Feb, 2023 | 13:20h | UTCCommentary: Breast Cancer Treatment Is Associated With Financial Toxicity Worldwide, Study Finds – AJMC
Related:
Not Just Nausea And Vomiting: Cancer Docs Now Worry About ‘Financial Toxicity’ – WBUR
Financial Toxicity and Cancer Treatment (PDQ®) – National Institute of Cancer
Commentary on Twitter
Financial toxicity for patients with breast cancer (pooled): 78% in LMICs and 35% in HICs; much higher than other health conditions, including other cancers. Policies to address this huge burden are critical to improve financial and health outcomes. https://t.co/eaB7nCvurU
— JAMA Network Open (@JAMANetworkOpen) February 9, 2023
SR | Antipsychotic exposure is an independent risk factor for breast cancer
17 Feb, 2023 | 12:41h | UTC
RCT | Laser treatment does not improve sexual dysfunction in survivors of breast cancer
16 Feb, 2023 | 15:19h | UTCInvited commentary: Genitourinary Syndrome of Menopause and the False Promise of Vaginal Laser Therapy – JAMA Network Open
Related:
RCT | Laser no better than sham treatment for genitourinary syndrome of menopause
M-A | Carbon dioxide laser vs. vaginal estrogen for genitourinary syndrome of menopause.
Perspective: From vaginal laser treatment to spa breaks – it’s the great menopause gold rush.
Commentary on Twitter
The LIGHT Trial RCT: Vaginal laser therapy does not improve sexual dysfunction/genitourinary syndrome of menopause in breast cancer survivors receiving aromatase inhibitors when added to first line therapy based on moisturizers and vibrator stimulation. https://t.co/jdVDgHe9HC
— JAMA Network Open (@JAMANetworkOpen) February 10, 2023
Reconstructive burnout after mastectomy: implications for patient selection
16 Feb, 2023 | 15:02h | UTCCommentary: One in Four Patients Experience Breast Reconstruction Burnout – HealthDay
Development and validation of a genomic profile for the omission of local adjuvant radiation in breast cancer
16 Feb, 2023 | 14:39h | UTC
RCT | Preoperative MRI in breast cancer did not influence local relapse-free survival, overall survival, or reoperation rates
15 Feb, 2023 | 15:57h | UTCSummary: This study investigated the impact of preoperative magnetic resonance imaging (MRI) on survival and surgical outcomes in conservative surgery for breast cancer. The randomized controlled trial included female participants with stage 0-III breast cancer, eligible for breast-conserving surgery. The study found that preoperative MRI increased the rate of mastectomies by 8% compared to routine radiologic exams using mammography and ultrasound. However, preoperative MRI did not impact the rates of local relapse-free survival, overall survival, or reoperation.*
*Note: This summary was created through the collaboration of a medical editor and ChatGPT.
M-A | Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials
9 Feb, 2023 | 13:37h | UTC
Cohort Study | Risk of primary hematologic cancers following incident non-metastatic breast cancer
8 Feb, 2023 | 12:11h | UTC
M-A | Risk of second primary cancer among breast cancer patients
6 Feb, 2023 | 13:10h | UTC
SR | Partial breast irradiation for breast cancer
3 Feb, 2023 | 14:06h | UTCPartial Breast Irradiation for Breast Cancer – Agency for Healthcare Research and Quality
SR | Immediate breast reconstruction uptake in older women with primary breast cancer
1 Feb, 2023 | 13:04h | UTC
Perspective | Endocrine treatment for 5 years or radiation for 5 days for patients with early breast cancer older than 65 years
26 Jan, 2023 | 12:04h | UTC
Commentary from the author on Twitter
🚨Hot off the press @JCO_ASCO: For decades we have been offering RT omission for early #bcsm patients, here we discuss how tides have changed and its time to omit hormonal therapy and treat with RT instead @TaghianAlphonse @MGHBreastOnc @LurieCancer
— George E. Naoum, MD, MMSCI (@George_E_Naoum) December 20, 2022
RCT | Breast-cancer–related lymphedema after reverse lymphatic mapping and selective axillary dissection vs. standard surgical treatment of axilla
24 Jan, 2023 | 14:15h | UTC
Commentary on Twitter
New & available #OpenAccess | Occurrence of breast-cancer–related #lymphedema after reverse lymphatic mapping and selective axillary dissection versus standard surgical treatment of axilla: A two-arm randomized clinical trial https://t.co/fXB7PfysCH @OncoAlert pic.twitter.com/wWNhC9BMvY
— ACS Journal Cancer (@JournalCancer) October 20, 2022
RCT | Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer
20 Jan, 2023 | 14:20h | UTCAbemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries:
Interim Analysis of Overall Survival in the monarchE Trial – The ASCO Post
Commentary on Twitter
https://twitter.com/DrYukselUrun/status/1600233075455143937
Review | Role of immunotherapy in breast cancer
18 Jan, 2023 | 14:03h | UTCRole of Immunotherapy in Breast Cancer – JCO Oncology Practice
RCT | Cosmetic results and side effects of accelerated partial-breast irradiation vs. whole-breast irradiation for low-risk invasive carcinoma of the breast
15 Jan, 2023 | 19:53h | UTCCosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter
5yr results of the phase 3 #IRMAtrial: EBRT #APBI b.i.d. associated with slightly increased rate of moderate soft tissue and bone toxicity and a slightly inferior cosmesis, though overall toxicity was in an acceptable range @JCO_ASCO #BCSM @OncoAlert https://t.co/8LHE2ut3t2
— Bruno Meduri (@brunomeduri) January 9, 2023
ASCO Guideline Update | Chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor–negative metastatic breast cancer
13 Jan, 2023 | 13:28h | UTC
Cohort Study | Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2
13 Jan, 2023 | 13:14h | UTC
Post-trial follow-up | Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer.
15 Dec, 2022 | 13:29h | UTCFluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Dose-Dense Adjuvant Chemotherapy “Optimal” for High-Risk Early Breast Cancer – Cancer Therapy Advisor
Commentary on Twitter
Online first: end-of-study results from the randomised, phase 3 GIM2 trial: #fluorouracil and dose-dense adjuvant #chemotherapy in patients with #early-stage #breastcancer https://t.co/9YD5w9aLY2 pic.twitter.com/RmPdi37sQB
— The Lancet Oncology (@TheLancetOncol) November 10, 2022
Post-trial follow-up | Radiotherapy vs. surgery of the axilla after a positive sentinel node in breast cancer.
14 Dec, 2022 | 14:42h | UTCRadiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: ART Preferred Over ALND in Sentinel Node-Positive Early Breast Cancer – Cancer Therapy Advisor
RCT | Mepitel film for the prevention of acute radiation dermatitis in breast cancer.
12 Dec, 2022 | 12:40h | UTCMepitel Film for the Prevention of Acute Radiation Dermatitis in Breast Cancer: A Randomized Multicenter Open-Label Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
RCT | Trastuzumab deruxtecan vs. trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.
8 Dec, 2022 | 12:49h | UTC